Ignite Creation Date:
2024-05-05 @ 4:52 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00337389
Status:
UNKNOWN
Last Update Posted:
2007-11-19
First Post:
2006-06-14
Brief Title:
Phase III Randomized Study of 5-FU CoFactor and Avastin vs 5-FU LV and Avastin for First-Line Colorectal Cancer
Sponsor:
Mast Therapeutics Inc
Organization:
Mast Therapeutics Inc
Study Overview
Official Title:
A Phase III Multi-Center Randomized Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-Fluorouracil 5-FU Plus Bevacizumab Versus Leucovorin and 5-FU Plus Bevacizumab as Initial Treatment for Metastatic Colorectal Carcinoma
Status:
UNKNOWN
Status Verified Date:
2007-11
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare the progression-free survival time PFS in patients treated with 5-FU modulated with CoFactor plus bevacizumab to 5-FU modulated with leucovorin plus bevacizumab in patients with Metastatic Colorectal Cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None